Special Issue "Immunogenic Effects of Electroporation-Based Treatments"

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: 25 March 2022.

Special Issue Editors

Prof. Dr. Emanuela Signori
E-Mail Website
Guest Editor
National Research Council, Institute of Translational Pharmacology (CNR-IFT), 00133 Rome, Italy
Interests: oncoimmunology; gene electrotransfer; DNA immunization; electroporation; plasmid DNA; electrochemotherapy
Special Issues and Collections in MDPI journals
Prof. Dr. Maja Čemažar
E-Mail Website
Guest Editor
National Research Council—Institute of Translational Pharmacology (CNR-IFT), Via Fosso del Cavaliere 100, Rome, Italy
Interests: gene electrotransfer; cancer gene therapy; electroporation; plasmid DNA; electrochemotherapy
Special Issues and Collections in MDPI journals
Prof. Mariangela De Robertis
E-Mail Website
Guest Editor
Dept. of Biosciences, Biotechnology and Biopharmaceutics, University of Bari “A. Moro”, 70121 Bari BA, Italy
Interests: gene electrotransfer; DNA immunization; electroporation
Prof. Loreé C. Heller
E-Mail Website
Guest Editor
Department of Medical Engineering, University of South Florida, 4202 E Fowler Avenue, Tampa, FL 33620, USA
Interests: gene therapy; pattern recognition; electroporation
Prof. Dr. Richard Heller
E-Mail Website
Guest Editor
Department of Medical Engineering, University of South Florida, Tampa, FL 33612, USA
Interests: gene therapy; electrotransfer; cancer; melanoma; vaccines; immunotherapy; electroporation
Special Issues and Collections in MDPI journals

Special Issue Information

Dear Colleagues,  

Studies in the field of immunology are revealing an attractive set of novel and different therapeutic approaches to treat cancer and infectious diseases. Electroporation, also named electropermeabilization (EP), is an efficient and safe technique based on the application of voltage pulses of sufficient strength and duration to generate transient membrane permeabilization/poration, thus allowing the delivery of drugs or genetic material into the target cells via electrotransfer. Past and recent results underline the capability of EP to influence the immune system response: following EP treatments, different innate and adaptive immune cells can be recruited, influencing immune responses at local and distant levels. Due to this property, many studies in the field of immunization by electroporation have been undertaken.

Intramuscular and skin gene electrotransfer (GET) represents a minimal invasive strategy to employ in immunotherapy and/or vaccination against infectious and cancer diseases, and to treat wound healing. Electrochemotherapy (ECT), irreversible electroporation (IRE), nano-pulse stimulation (NPS) and calcium electroporation (CaEP) are becoming more widely used in clinical protocols to treat different kinds of cancer with positive outcomes. Employment of nucleic acids for the development of new vaccines to deliver via electroporation is emerging as a new platform at the front line of the pandemic.

The aim of this Special Issue is to revive the success of a previous one, by pointing out the advancements in the field and eliciting a debate. Induction of immunological effects and enhancement of the immune system response induced by genetic vaccines and/or immunomodulatory molecules, administered alone or in combination with other therapeutic treatments by EP, will be discussed. Presentations of results on the immunological effects of drugs delivered by electric fields in pre-clinical and clinical trials will be very welcome as well.

The peer-reviewed papers (research articles or reviews) will provide a cross-section on the ongoing research in the field of electroporation applied to cancer and infectious diseases.

Prof. Emanuela Signori
Prof. Maja Čemažar
Prof. Mariangela De Robertis
Prof. Loreé C. Heller
Prof. Richard Heller
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • electroporation
  • vaccines
  • oncoimmunology

Published Papers

This special issue is now open for submission.
Back to TopTop